{"filing":{"accession_number":"0001636282-26-000098","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"syre-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/syre-20260804.htm"},"events":[{"id":24254,"run_id":21961,"accession_number":"0001636282-26-000098","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Item 2.02 discloses Spyre's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The press release announces Q2 2026 financial results including cash position ($1.145 billion), R\u0026D expenses ($65.5 million), G\u0026A expenses ($16.1 million), and net loss ($36.2 million), along with clinical program updates. This is a standard earnings release disclosure for a clinical-stage biotech company, material to investors assessing the company's financial position and cash runway into 2029.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24746,"accession_number":"0001636282-26-000098","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Spyre's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The press release announces Q2 2026 financial results including cash position ($1.145 billion), R\u0026D expenses ($65.5 million), G\u0026A expenses ($16.1 million), and net loss ($36.2 million), along with clinical program updates. This is a standard earnings release disclosure for a clinical-stage biotech company, material to investors assessing the company's financial position and cash runway into 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:16:25.692239+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24746,"accession_number":"0001636282-26-000098","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Spyre's second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The press release announces Q2 2026 financial results including cash position ($1.145 billion), R\u0026D expenses ($65.5 million), G\u0026A expenses ($16.1 million), and net loss ($36.2 million), along with clinical program updates. This is a standard earnings release disclosure for a clinical-stage biotech company, material to investors assessing the company's financial position and cash runway into 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:16:25.692239+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-08-04"}]}